Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1388 CRB-601, an integrin αvβ8 blocking antibody entering phase I: pre-clinical and translational biomarkers for indication selection
Compose a Response to This Article
Other responses
No responses have been published for this article.
